Literature DB >> 28636782

Changing trends in complications of chronic hepatitis C.

Mei Lu1, Jia Li1, Loralee B Rupp2, Yueren Zhou1, Scott D Holmberg3, Anne C Moorman3, Philip R Spradling3, Eyasu H Teshale3, Joseph A Boscarino4, Yihe G Daida5, Mark A Schmidt6, Sheri Trudeau1, Stuart C Gordon7.   

Abstract

BACKGROUND & AIMS: Chronic hepatitis C virus (HCV)-related complications have increased over the past decade.
METHODS: We used join-point regression modelling to investigate trends in these complications from 2006 to 2015, and the impact of demographics on these trends. Using data from the Chronic Hepatitis Cohort Study (CHeCS), we identified points at which the trend significantly changed, and estimated the annual percent change (APC) in rates of cirrhosis, decompensated cirrhosis and all-cause mortality, adjusted by race, sex and age.
RESULTS: Among 11,167 adults with chronic HCV infection, prevalence of cirrhosis increased from 20.8% to 27.6% from 2006 to 2015, with adjusted annual percentage change (aAPC) of 1.2 (p <. 01). Although incidence of all-cause mortality increased from 1.8% in 2006 to 2.9% in 2015, a join-point was identified at 2010, with aAPCs of 9.6 before (2006 < 2010; p < .01) and -5.2 after (2010 ≤ 2015; p < .01), indicating a decrease in mortality from 2010 and onward. Likewise, overall prevalence of decompensated cirrhosis increased from 9.3% in 2006 to 10.4% in 2015, but this increase was confined to patients 60 or older (aAPC = 1.5; p = .023). Asian American and Black/African American patients demonstrated significantly higher rates of cirrhosis than White patients, while older patients and men demonstrated higher rates of cirrhosis and mortality.
CONCLUSIONS: Although cirrhosis and mortality among HCV-infected patients in the US have increased over the past decade, all-cause mortality has decreased in recent years.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  African Americans; Asian Americans; cirrhosis; decompensated cirrhosis

Mesh:

Year:  2017        PMID: 28636782      PMCID: PMC5777910          DOI: 10.1111/liv.13501

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  28 in total

1.  Toward a more accurate estimate of the prevalence of hepatitis C in the United States.

Authors:  Brian R Edlin; Benjamin J Eckhardt; Marla A Shu; Scott D Holmberg; Tracy Swan
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

2.  Comparison of characteristics of treated and non-treated patients with Hepatitis C infection.

Authors:  C Bradley Hare; Jonathan A Morris; Alice Chu; Vincent Gotz; Jacqueline J Loveland; David Hodes; Winslow Klaskala
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-02       Impact factor: 2.890

3.  Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.

Authors:  Stuart C Gordon; Paul J Pockros; Norah A Terrault; Robert S Hoop; Ami Buikema; David Nerenz; Fayez M Hamzeh
Journal:  Hepatology       Date:  2012-10-09       Impact factor: 17.425

4.  Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.

Authors:  Philip R Spradling; Jian Xing; Loralee B Rupp; Anne C Moorman; Stuart C Gordon; Mei Lu; Eyasu H Teshale; Joseph A Boscarino; Mark A Schmidt; Yihe G Daida; Scott D Holmberg
Journal:  J Clin Gastroenterol       Date:  2018-08       Impact factor: 3.062

5.  Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010.

Authors:  Reena Mahajan; Jian Xing; Stephen J Liu; Kathleen N Ly; Anne C Moorman; Loralee Rupp; Fujie Xu; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2014-02-12       Impact factor: 9.079

6.  Surveillance for acute viral hepatitis--United States, 2006.

Authors:  Annemarie Wasley; Scott Grytdal; Kathleen Gallagher
Journal:  MMWR Surveill Summ       Date:  2008-03-21

7.  Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort.

Authors:  Scott D Holmberg; Mei Lu; Loralee B Rupp; Lois E Lamerato; Anne C Moorman; Vinutha Vijayadeva; Joseph A Boscarino; Emily M Henkle; Stuart C Gordon
Journal:  Clin Infect Dis       Date:  2013-04-16       Impact factor: 9.079

8.  Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma.

Authors:  Mei Lu; Jia Li; Loralee B Rupp; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Yueren Zhou; Joseph A Boscarino; Mark A Schmidt; Lois E Lamerato; Connie Trinacty; Sheri Trudeau; Stuart C Gordon
Journal:  J Viral Hepat       Date:  2016-03-30       Impact factor: 3.728

9.  Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection.

Authors:  Mei Lu; Jia Li; Talan Zhang; Loralee B Rupp; Sheri Trudeau; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Fujie Xu; Joseph A Boscarino; Mark A Schmidt; Vinutha Vijayadeva; Stuart C Gordon
Journal:  Clin Gastroenterol Hepatol       Date:  2016-01-22       Impact factor: 11.382

10.  The validity of serum markers for fibrosis staging in chronic hepatitis B and C.

Authors:  J Li; S C Gordon; L B Rupp; T Zhang; J A Boscarino; V Vijayadeva; M A Schmidt; M Lu
Journal:  J Viral Hepat       Date:  2014-01-29       Impact factor: 3.728

View more
  2 in total

Review 1.  Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings.

Authors:  Anne C Moorman; Loralee B Rupp; Stuart C Gordon; Yuna Zhong; Jian Xing; Mei Lu; Joseph A Boscarino; Mark A Schmidt; Yihe G Daida; Eyasu H Teshale; Philip R Spradling; Scott D Holmberg
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

2.  Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C.

Authors:  Elizabeth A McGlynn; John L Adams; Jason Kramer; Amandeep K Sahota; Michael J Silverberg; Elizabeth Shenkman; David R Nelson
Journal:  JAMA Netw Open       Date:  2019-06-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.